Comments, Opinions, and Brief Case Reports
May 09, 2005

Successful Treatment of Relapsed Acute Promyelocytic Leukemia in a Patient Receiving Continuous Ambulatory Peritoneal Dialysis With Oral Arsenic Trioxide

Author Affiliations

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Intern Med. 2005;165(9):1067-1068. doi:10.1001/archinte.165.9.1067

Serious medical comorbidities generally preclude curative therapies for patients with leukemia. Arsenic trioxide (As2O3), both intravenous and oral, is highly effective for acute promyelocytic leukemia (APL).1 As arsenic is eliminated mainly by renal excretion, uremic patients are considered unsuitable for arsenic trioxide therapy. To our knowledge, there are no data on arsenic clearance during dialysis. A patient with APL who was receiving continuous ambulatory peritoneal dialysis (CAPD) was successfully treated with oral arsenic trioxide. We took this unique opportunity to study arsenic clearance during CAPD.

First Page Preview View Large
First page PDF preview
First page PDF preview